Mission
CORIELL'S MISSION IS TO ACCELERATE SCIENTIFIC DISCOVERY BY GENERATING, BANKING, STORING AND DISTRIBUTING WORLD-CLASS BIOMATERIALS, AND CONDUCTING GROUNDBREAKING RESEARCH IN GENETICS AND EPIGENETICS.
Public Charity
CORIELL INSTITUTE FOR MEDICAL RESEARCH INC
CORIELL INSTITUTE FOR MEDICAL RESEARCH INC is a Public Charity headquartered in CAMDEN, NJ. Financial data from the 2025 filing: $25.2M revenue, $23.1M expenses, $37.7M total assets. 20 publicly reported grants to this organization, totaling roughly $2.8M, appear in IRS filings.
EIN: 210672684
CAMDEN, NJ
Biological & Life Sciences
NTEE: U50
Latest filing: 2025
Total Revenue$25.2M
Total Expenses$23.1M
Total Assets$37.7M
Grant Records20
Funding Total$2.8M
Filing Years2021–2025
Where $100 goes at Coriell Institute for Medical Research Inc
How Coriell Institute for Medical Research Inc divides every $100 it spends, from its own Form 990 filings, averaged across 9 years.
$73
Programs
the work itself
$27
Management
running the organization
$0
Fundraising
none reported
No fundraising costs are reported. That often means fundraising runs through a separate affiliated organization that files its own return.
Inside the $73 for programs
$73
The Coriell Institute for Medical Research is a world-renowned biomedical research organization dedicated to preventing and curing disease
Source: Form 990 filings with the IRS, latest fiscal year 2025. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.
Sample Grants Received
Creating a biobank of patient-derived induced pluripotent stem cells. This project aims to establish a biobank of five unique lines of commercially-available induced pluripotent stem cells (iPSCs) from patient blood samples. The cellular reprogramming will be conducted by the Coriell Institute for Medical Research and samples will be housed and distributed through an additional partnership with the Orphan Disease Center at The University of Pennsylvania. Cell lines will be available to researchers in academic and for-profit research settings at a low cost, set to cover the long-term maintenance of the biobank effort.
$9,369
GENERAL SUPPORT
$1,000,000
Extramural Research Grant
$300,000
This project aims to establish a biobank of five unique lines of commercially-available induced pluripotent stem cells (iPSCs) from patient blood samples. The cellular reprogramming will be conducted by the Coriell Institute for Medical Research and samples will be housed and distributed through an additional partnership with the Orphan Disease Center at The University of Pennsylvania. Cell lines will be available to researchers in academic and for-profit research settings at a low cost, set to cover the long-term maintenance of the biobank effort.
$12,617
GENERAL SUPPORT
$833,333
Showing up to 5 of 20 total records — full history available with membership.
Officers & Directors
TRUSTEE
Annette Reboli
TRUSTEE (UNTIL 01/25)
Antonio Tillis Phd
TRUSTEE
Arnaud Bastien Md
TRUSTEE
Christopher Gibson Esq
CFO
Denise Buscher
PRESIDENT/CEO
Dr Jean-Pierre Issa
Officer compensation and complete director data available with membership.
Top Grant Purposes
Financial Trends
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2025 | $25.2M | $23.1M | $37.7M |
| 2024 | $32.1M | $24.2M | $33.6M |
| 2023 | $23.4M | $22.3M | $29.7M |
| 2022 | $23.3M | $20.3M | $27.6M |
| 2021 | $17.3M | $18.1M | $28.4M |
Between 2021 and 2025, reported annual revenue grew from $17.3M to $25.2M (+46%), with total assets most recently reported at $37.7M.
Interactive year-over-year charts and full filing details available with membership.